Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
(NASDAQ: ARVN) Delayed: 7.74 +0.07 (0.91%)
Previous Close $7.67    52 Week High $ 
Open $7.70    52 Week Low $ 
Day High $7.76    P/E N/A 
Day Low $7.48    EPS $ 
Volume 711,053       

(NASDAQ: ARVN) Delayed: 7.74 +0.07 (0.91%)
Previous Close $7.67    52 Week High $ 
Open $7.70    52 Week Low $ 
Day High $7.76    P/E N/A 
Day Low $7.48    EPS $ 
Volume 711,053